Amendment No. 2 to Collaboration and License AgreementBlueprint Medicines Corp • August 2nd, 2023 • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment”), dated as of July 27, 2023 (“Amendment 2 Effective Date”), between Blueprint Medicines Corporation (“Blueprint”) and Oncopia Therapeutics, Inc. d/b/a Proteovant Therapeutics, Inc. (“Proteovant”) amends that certain Collaboration and License Agreement, dated February 26, 2022 by and between Blueprint and Proteovant, as earlier amended on June 5, 2023 (the “Agreement”). Blueprint and the Proteovant are each referred to herein as a “Party” and, collectively, as the “Parties.” Capitalized terms used and not otherwise defined in this Amendment shall have the meanings set forth in the Agreement.
Amendment No. 1 to Collaboration and License AgreementBlueprint Medicines Corp • August 2nd, 2023 • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”), dated as of June 5, 2023 (“Amendment Effective Date”), between Blueprint Medicines Corporation (“Blueprint”) and Oncopia Therapeutics, Inc. d/b/a Proteovant Therapeutics, Inc. (“Proteovant”) amends that certain Collaboration and License Agreement, dated February 26, 2022 by and between Blueprint and Proteovant (the “Agreement”). Blueprint and the Proteovant are each referred to herein as a “Party” and, collectively, as the “Parties.” Capitalized terms used and not otherwise defined in this Amendment shall have the meanings set forth in the Agreement.
